Through the multiyear partnership, Moderna will use Caris’ library of deidentified data to advance the company’s oncology pipeline. Additionally, the partnership will focus on facilitating clinical trial design, discovering new biomarkers and characterizing resistance mechanisms, according to an Oct. 24 Caris news release.
Financial terms of the partnership were not disclosed.
“We are thrilled to partner with Moderna to impact and advance the field of cancer treatment with mRNA medicines, with a common goal of improving patient lives,” David Spetzler, PhD, president of Caris Life Sciences, said in the news release. “The aggregate strength of our combined molecular, data science and therapeutics technologies will support the predictive modeling of patient responses to therapies, and more generally, may help improve the probability of technical and regulatory success of Moderna’s innovative medicines.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.